Robert hugin update#

This strong performance supports raising our full-year financial guidance. Increased Revlimid duration of therapy and accelerating global launches of pomalidomide and Abraxane in pancreatic cancer fueled substantial volume and revenue growth.

The strong revenue and earnings growth reported this morning reflect the excellent operating performance of our teams. Our businesses across functions and geographies have outstanding momentum. Outstanding results produce the resources that allow us to invest in the discovery and development of tomorrow’s transformational therapies, and our teams across the globe are delivering. Operational excellence is the foundation of our business model.

Robert hugin update#

I appreciate the opportunity to update you on the excellent results of the quarter and the significant progress achieved advancing strategic corporate initiatives. Thanks Patrick, and thank you everyone for joining us this morning. I would now like to turn the call over to Bob. Finally, a reconciliation of the adjusted financial measures to the most comparable GAAP measures are available as part of the earnings release. These statements speak only as of today’s date and we undertake no duty to update or revise them. A description of these risks can be found in our most recent 10-Q on file with the SEC. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. The press release reporting our financial results in addition to the presentation for today’s webcast can be accessed by going to the Investor Relations section of the corporate website at Joining me in the room today with prepared remarks are Bob Hugin, our Chairman and Chief Executive Officer Jacquie Fouse, our Chief Financial Officer Mark Alles, who is Global Head of our Hematology and Oncology franchise and the Global Head of our Inflammation and Immunology franchise, Scott Smith.Īs a reminder, during today’s call we will be making forward-looking statements regarding our financial outlook in addition to regulatory and product development plans. Thanks, Nicole, and welcome everyone to our second quarter earnings conference call. I would now like to turn the conference over to Patrick Flanigan, Vice President, Investor Relations at Celgene. I would like to remind you that this call is being recorded. All participants will be in a listen-only mode until the question and answer session at the end of the conference. Good morning and welcome to the Celgene Second Quarter 2014 Earnings conference call. Patrick Flanigan – Vice President, Investor Relations Scott Smith – Global Head, Inflammation and Immunology Mark Alles – Global Head, Hematology and Oncology Jacqualyn Fouse – Executive Vice President, Chief Financial Officer

Robert Hugin – Chairman, Chief Executive Officer He received his undergraduate degree from Princeton University and an MBA from the University of Virginia Darden School of Business.Celgene Corporation ( NASDAQ: CELG) Q2 2014 Earnings Conference Call J9:00 AM ET

He also served on the board at Coley Pharmaceutical Group, Inc. (Old), a Trustee by Atlantic Health System, Inc., a Trustee by Chilton Memorial Hospital, a Chairman by HealthCare Institute of New Jersey, and an Infantry Officer by United States Marine Corps. (Ireland), an Independent Director by Danaher Corp., a Chairman by Pharmaceutical Research & Manufacturers of America, an Executive Chairman by Celgene Ltd., an Independent Director by The Medicines Co., an Executive Chairman by Celgene Corp., a Managing Director by J.P. Hugin was previously employed as an Independent Director by Allergan Ltd. Ltd., Chubb Ltd., Choose New Jersey, Nereid Therapeutics, Inc., Darden School Foundation, Family Promise, Princeton University and University of Virginia Darden School of Business. He is on the Board of Directors at Biohaven Pharmaceutical Holding Co. and an Independent Director at Chubb Ltd. Hugin is an Independent Director at Biohaven Pharmaceutical Holding Co.